Jonathan C Hsu1, Paul S Chan2, Fengming Tang2, Thomas M Maddox3, Gregory M Marcus4. 1. Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine, University of California, San Diego. Electronic address: Jonathan.Hsu@ucsd.edu. 2. Mid America Heart Institute, Kansas City, Mo. 3. VA Eastern Colorado Health Care System/University of Colorado School of Medicine, Denver. 4. Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California, San Francisco.
Abstract
BACKGROUND: Patients with paroxysmal and persistent atrial fibrillation experience a similar risk of thromboembolism. Therefore, consensus guidelines recommend anticoagulant therapy in those at risk for thromboembolism irrespective of atrial fibrillation classification. We sought to examine whether there are differences in rates of appropriate oral anticoagulant treatment among patients with paroxysmal vs persistent atrial fibrillation in real-world cardiology practices. METHODS: We studied 71,316 outpatients with atrial fibrillation and intermediate to high thromboembolic risk (CHADS2 score ≥2) enrolled in the American College of Cardiology PINNACLE Registry between 2008 and 2012. Using hierarchical modified Poisson regression models adjusted for patient characteristics, we examined whether anticoagulant treatment rates differed between patients with paroxysmal vs persistent atrial fibrillation. RESULTS: The majority of outpatients (78.4%, n = 55,905) had paroxysmal atrial fibrillation. In both unadjusted and multivariable adjusted analyses, patients with paroxysmal atrial fibrillation were less frequently prescribed oral anticoagulant therapy than those with persistent atrial fibrillation (50.3% vs 64.2%; adjusted risk ratio [RR] 0.74; 95% confidence interval [CI], 0.72-0.76). Instead, patients with paroxysmal atrial fibrillation were prescribed more frequently only antiplatelet therapy (35.1% vs 25.0%; adjusted RR 1.77; 95% CI, 1.69-1.86) or neither antiplatelet nor anticoagulant therapy (14.6% vs 10.8%; adjusted RR 1.35; 95% CI, 1.26-1.44; P < .0001 for differences across all 3 comparisons). CONCLUSIONS: In a large, real-world cardiac outpatient population, patients with paroxysmal atrial fibrillation with a moderate to high risk of stroke were less likely to be prescribed appropriate oral anticoagulant therapy and more likely to be prescribed less effective or no therapy for thromboembolism prevention.
BACKGROUND:Patients with paroxysmal and persistent atrial fibrillation experience a similar risk of thromboembolism. Therefore, consensus guidelines recommend anticoagulant therapy in those at risk for thromboembolism irrespective of atrial fibrillation classification. We sought to examine whether there are differences in rates of appropriate oral anticoagulant treatment among patients with paroxysmal vs persistent atrial fibrillation in real-world cardiology practices. METHODS: We studied 71,316 outpatients with atrial fibrillation and intermediate to high thromboembolic risk (CHADS2 score ≥2) enrolled in the American College of Cardiology PINNACLE Registry between 2008 and 2012. Using hierarchical modified Poisson regression models adjusted for patient characteristics, we examined whether anticoagulant treatment rates differed between patients with paroxysmal vs persistent atrial fibrillation. RESULTS: The majority of outpatients (78.4%, n = 55,905) had paroxysmal atrial fibrillation. In both unadjusted and multivariable adjusted analyses, patients with paroxysmal atrial fibrillation were less frequently prescribed oral anticoagulant therapy than those with persistent atrial fibrillation (50.3% vs 64.2%; adjusted risk ratio [RR] 0.74; 95% confidence interval [CI], 0.72-0.76). Instead, patients with paroxysmal atrial fibrillation were prescribed more frequently only antiplatelet therapy (35.1% vs 25.0%; adjusted RR 1.77; 95% CI, 1.69-1.86) or neither antiplatelet nor anticoagulant therapy (14.6% vs 10.8%; adjusted RR 1.35; 95% CI, 1.26-1.44; P < .0001 for differences across all 3 comparisons). CONCLUSIONS: In a large, real-world cardiac outpatient population, patients with paroxysmal atrial fibrillation with a moderate to high risk of stroke were less likely to be prescribed appropriate oral anticoagulant therapy and more likely to be prescribed less effective or no therapy for thromboembolism prevention.
Authors: Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano Journal: Circulation Date: 2006-08-15 Impact factor: 29.690
Authors: Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns Journal: Eur Heart J Date: 2006-05-26 Impact factor: 29.983
Authors: S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf Journal: Lancet Date: 2006-06-10 Impact factor: 79.321
Authors: Nicole L Glazer; Sascha Dublin; Nicholas L Smith; Benjamin French; Lisa A Jackson; Jennifer B Hrachovec; David S Siscovick; Bruce M Psaty; Susan R Heckbert Journal: Arch Intern Med Date: 2007-02-12
Authors: Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin Journal: Circulation Date: 2004-08-16 Impact factor: 29.690
Authors: Matthew R Reynolds; Jignesh Shah; Vidal Essebag; Brian Olshansky; Paul A Friedman; Tomy Hadjis; Robert Lemery; Tristram D Bahnson; David S Cannom; Mark E Josephson; Peter Zimetbaum Journal: Am J Cardiol Date: 2006-01-04 Impact factor: 2.778
Authors: Melanie Gunawardene; S Willems; B Schäffer; J Moser; R Ö Akbulak; M Jularic; C Eickholt; J Nührich; C Meyer; P Kuklik; S Sehner; V Czerner; B A Hoffmann Journal: Clin Res Cardiol Date: 2016-07-19 Impact factor: 5.460
Authors: Alan S Go; Kristi Reynolds; Jingrong Yang; Nigel Gupta; Judith Lenane; Sue Hee Sung; Teresa N Harrison; Taylor I Liu; Matthew D Solomon Journal: JAMA Cardiol Date: 2018-07-01 Impact factor: 14.676
Authors: Alejandra Gullón; Francesc Formiga; Jesús Díez-Manglano; José María Mostaza; José María Cepeda; Antonio Pose; Jesús Castiella; Carmen Suárez-Fernández Journal: Intern Emerg Med Date: 2018-09-06 Impact factor: 3.397
Authors: Clare L Atzema; Cynthia A Jackevicius; Alice Chong; Paul Dorian; Noah M Ivers; Ratika Parkash; Peter C Austin Journal: CMAJ Date: 2019-12-09 Impact factor: 8.262
Authors: David R Vinson; E Margaret Warton; Dustin G Mark; Dustin W Ballard; Mary E Reed; Uli K Chettipally; Nimmie Singh; Sean Z Bouvet; Bory Kea; Patricia C Ramos; David S Glaser; Alan S Go Journal: West J Emerg Med Date: 2018-02-12
Authors: Jeffrey M Ashburner; Steven J Atlas; Shaan Khurshid; Lu-Chen Weng; Olivia L Hulme; Yuchiao Chang; Daniel E Singer; Patrick T Ellinor; Steven A Lubitz Journal: J Gen Intern Med Date: 2018-08-03 Impact factor: 6.473
Authors: Christopher T Sciria; Thomas M Maddox; Lucas Marzec; Benjamin Rodwin; Salim S Virani; Amarnath Annapureddy; James V Freeman; Ali O'Hare; Yuyin Liu; Yang Song; Gheorghe Doros; Yue Zheng; Jane J Lee; Ramesh Daggubati; Lina Vadlamani; Christopher Cannon; Nihar R Desai Journal: Clin Cardiol Date: 2020-05-06 Impact factor: 3.287